Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America

Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar Expands Har

INCHEON, Korea--(BUSINESS WIRE)-- #Byooviz--Samsung Bioepis Co., Ltd. today announced the relaunch o

Harrow relaunches Verkazia for VKC treatment, targeting pediatric eye disease with a steroid-sparing

VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, pat

Cantor Fitzgerald analyst Steve Seedhouse maintains Harrow (NASDAQ:HROW) with a Overweight and lo

U.S. stock futures lower, Nasdaq down 200 points. AST SpaceMobile shares dip 11% after reporting wor

Harmonic Inc (HLIT) rose in pre-market trading after beating earnings expectations & raising gui

Harrow (NASDAQ:HROW) affirms FY2026 sales outlook from $350.000 million-$365.000 million to $350.000

Harrow (NASDAQ:HROW) reported quarterly losses of $(0.74) per share which missed the analyst consens

LogiCare3PL today announced it has been selected by Harrow, Inc. (NASDAQ:HROW) as a distribution par

B. Riley Securities analyst Mayank Mamtani reiterates Harrow (NASDAQ:HROW) with a Buy and lowers

The 2030 Notes will be guaranteed on a senior unsecured basis by the Company's existing and futu

Cantor Fitzgerald analyst Steve Seedhouse maintains Harrow (NASDAQ:HROW) with a Overweight and lo

HC Wainwright & Co. analyst Yi Chen maintains Harrow (NASDAQ:HROW) with a Buy and raises the

Harrow stock drops after earnings miss and weak 2026 outlook, despite revenue growth and new product

MDB stock fell 27.2% in pre-market trading after reporting Q4 earnings of $1.65 per share, revenue o

The planned Phase 3 study is a randomized, placebo-controlled, double-masked, multicenter clinical t

Shares of Ouster Inc (NASDAQ:OUST) rose sharply in pre-market trading after the company reported bet

Harrow (NASDAQ:HROW) reported quarterly earnings of $0.17 per share which missed the analyst consens

U.S. stock futures lower, Dow futures down 1%. Yatsen Holding shares fall 10.1%, while other stocks

Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to  the Office

Ladenburg Thalmann analyst Jeffrey Cohen maintains Harrow (NASDAQ:HROW) with a Buy and raises the

HC Wainwright & Co. analyst Yi Chen maintains Harrow (NASDAQ:HROW) with a Buy and raises the

B. Riley Securities analyst Mayank Mamtani reiterates Harrow (NASDAQ:HROW) with a Buy and raises

Lake Street analyst Thomas Flaten maintains Harrow (NASDAQ: HROW) with a Buy and raises the price

HC Wainwright & Co. analyst Yi Chen reiterates Harrow (NASDAQ: HROW) with a Buy and maintains

Harrow, Inc. (NASDAQ: HROW), a U.S.-based provider of ophthalmic disease management solutions, annou

Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North Americ

B. Riley Securities analyst Mayank Mamtani maintains Harrow (NASDAQ:HROW) with a Buy and raises t

Craig-Hallum analyst Chase Knickerbocker maintains Harrow (NASDAQ:HROW) with a Buy and raises the

BTIG analyst Thomas Shrader maintains Harrow (NASDAQ:HROW) with a Buy and raises the price target

HC Wainwright & Co. analyst Yi Chen maintains Harrow (NASDAQ:HROW) with a Buy and raises the

Harrow (NASDAQ:HROW) reported quarterly earnings of $0.24 per share which beat the analyst consensus